natgillin/translations-raw huggingface dataset:
VBP15 or VBP6 for use according to Claim 1, wherein said muscular dystrophy is selected from the group consisting of Duchenne muscular dystrophy, Becker muscular dystrophy, limb girdle muscular dystrophy, congenital muscular dystrophy, facioscapulohumeral muscular dystrophy, myotonic muscular dystrophy, oculopharyngeal muscular dystrophy, distal muscular dystrophy, and Emery-Dreifuss muscular dystrophy. 
VBP15 ili VBP6 za uporabu u skladu s patentnim zahtjevom 1, pri čemu je navedena mišićna distrofija izabrana iz grupe koja sadrži Duchenne mišićnu distrofiju, mišićnu distrofiju donjih udova, kongentialnu mišićnu distrofiju, facioskapulohumeralnu mišićnu distrofiju, miotoničnu mišićnu distrofiju, okulofaringealnu mišićnu distrofiju, distalnu mišićnu distrofiju i Emery-Dreifuss mišićnu distrofiju.
VBP15 or VBP6 for use according to Claim 1, wherein said muscular dystrophy is Duchenne muscular dystrophy. 
VBP15 ili VBP6 za uporabu u skladu s patentnim zahtjevom 1, pri čemu je navedena mišićna distrofija Duchenne mišićna distrofija.
VBP15 or VBP6 for use according to Claim 1, wherein the compound is VBP15. 
VBP15 ili VBP6 za uporabu u skladu s patentnim zahtjevom 1, pri čemu je spoj VBP15.
The compound for use according to Claim 4, wherein said muscular dystrophy is Duchenne muscular dystrophy. 
Spoj za uporabu u skladu s patentnim zahtjevom 4, pri čemu je navedena mišićna distrofija Duchenne mišićna distrofija.
The composition of claim 1 in which m is zero to two. 
Postupak sukladno zahtjevu 1 pri čemu m je nula do dva.
The composition of claim 2 in which R2 is C1-C6 alkyl. 
Postupak sukladno zahtjevu 2 pri čemu R2 je C1-C6 alkil.
The composition of claim 5 in which each compound of formula (I) is present at a level from 0.05 ppm to 50 ppm. 
Postupak sukladno zahtjevu 5 pri čemu je svaki sastojak formule (I) prisutan u razini od 0.05 ppm do 50 ppm.
The composition of claim 7 in which R1 is methyl and m is zero. 
Postupak sukladno zahtjevu 7 pri čemu R1 je metil i m je nula.
wherein the water content in the sodium nitrite is no greater than 0.5% by weight; 
pri čemu sadržaj vode u natrijevom nitritu nije veći od 0,5 tež%;
wherein the sodium nitrite contains no greater than 10 ppm, no greater than 100 ppm, no greater than 500 ppm, no greater than 1000 ppm, or no greater than 5000 ppm of organic volatile impurities; 
pri čemu natrijev nitrit ne sadrži više od 10 ppm, ne više od 100 ppm, ne više od 500 ppm, ne više od 1000 ppm, ili ne više od 5000 ppm organskih hlapljivih nečistoća;
wherein the total non-volatile organic carbon content in the sodium nitrite is no greater than 2.5 ppm, or no greater than 10 ppm; 
pri čemu ukupni sadržaj nehlapljivog organskog ugljika u natrijevom nitritu nije veći od 2,5 ppm ili nije veći od 10 ppm;
wherein the sodium nitrite has total aerobic count of microbial load of no greater than 100 CFU/g, has total yeast and mold count of no greater than 20 CFU/g, contains no greater than 0.25 EU/mg of bacterial endotoxins; 
pri čemu natrijev nitrit ima ukupan aerobni broj mikrobnog opterećenja ne veći od 100 CFU/g, u kupni broj kvasca i plijesni nije veći od 20 CFU/g, ne sadrži više od 0,25 EU/mg bakterijskih endotoksina;
wherein the sodium nitrite contains no less than 97% by weight and no greater than 101% by weight of sodium nitrite as measured by USP colormetric assay; and wherein the heavy metal content in the sodium nitrite is no greater than 10 ppm. 
pri čemu natrijev nitrit sadrži najmanje 97 tež% i ne više od 101 tež% natrijevog nitrita, mjereno USP kolormetrijskim testom; i pri čemu sadržaj teških metala u natrijevom nitritu nije veći od 10 ppm.
A process for manufacturing a transfer medium suitable for ink-jet printing, comprising the steps: 
Postupak za proizvodnju medija za prijenos, naročito za ink-jet tiskanje, koji sadrži korake:
applying a first aqueous liquid to a front side of a base substrate to be printed, wherein the base substrate has a porosity of 0-1,000 ml/min before application of the first aqueous liquid, and the first aqueous liquid comprises at least one hydrophilic organic polymer or a salt thereof and at least one water-soluble alkaline salt, wherein the hydrophilic organic polymer is selected from the group consisting of polyacrylic acid, and a copolymer comprising at least one compound selected from the group consisting of an acrylic acid, and acrylic acid ester, and wherein the water-soluble alkaline salt comprises (hydrogen)carbonate and a silicate, and subsequent drying; and optionally applying a second aqueous liquid to a reverse side of the base substrate and subsequent drying, the second liquid optionally comprising a hydrophilic polymer or a salt thereof. 
nanošenje prve vodene tekućine na prednju stranu osnovne podloge za ispis, pri čemu osnovna podloga ima poroznost od 0-1,000 ml/min, poželjno 0-200 ml/min, poželjnije 0-100 ml/min, mjereno prema ISO standardu 5636-3, te prva vodena tekućina sadrži barem jedan hidrofilni organski polimer ili njegovu sol, i naknadno sušenje; i proizvoljno nanošenje druge vodene tekućine na suprotnu stranu osnovne podloge i naknadno sušenje, te druga tekućina proizvoljno sadrži hidrofilni polimer ili njegovu sol, pri čemu je hidrofilni organski polimer odabran iz skupine koju čine poliakrilna kiselina, poliakrilester, poliakrilamid, kopolimer koji sadrži barem jedno od akrilnu kiselinu, ester akrilne kiseline, akril amid i vinil acetat ili njihove soli, poželjno poliakrilnu kiselinu ili njezinu sol (poliakrilat), pri čemu je osnovna podloga odabrana iz skupine koju čine papir ili metal.
The process according to claim 1, wherein the hydrophilic organic polymer is present in the first aqueous liquid from 1-50 wt. %, based on the total mass of the first aqueous liquid. 
Postupak prema patentnom zahtjevu 1, naznačen time što je hidrofilni organski polimer prisutan u prvoj vodenoj tekućini od 1-50 mas.-%, poželjno 2-20 mas.-%, u odnosu na ukupnu masu prve vodene tekućine.
The process according to claim 1, wherein after drying of the first aqueous liquid, a coating having a dry weight of 0.2-25 g/m2 is obtained on the front side of the base substrate. The process according to claim 14, wherein said coating has a dry weight of 0.2-5 g/m2. 
Postupak prema bilo kojem od patentnih zahtjeva 1-7, naznačen time što se nakon sušenja prve vodene tekućine na prednjoj strani osnovne podloge dobije prevlaka suhe težine 0.2-25 g/m2, poželjno 0.2-5 g/m2.
A heating system (100) to heat a main heating circulation, said heating system (100) comprising: 
Sustav za grijanje (100) za zagrijavanje glavnog kruga grijanja, navedeni sustav za grijanje (100) obuhvaća:
a control head (120) adapted to determine a temperature and a pressure of said primary heating liquid; 
kontrolnu glavu (120) prilagođenu da utvrdi temperaturu navedene primarne tekućine za grijanje;
characterized in that said heating system (100) further comprises metal fittings (205) being arranged at ends of at least some of said plurality of tubes (105), wherein said metal fittings (205) are adapted to provide an electric connection between said primary heating liquid and said ground potential; and 
navedeni sustav za grijanje (100) nadalje se sastoji od metalnih učvršćenja (205) koja se postavljaju na barem nekoliko navedenih skupova cijevi (105), pri čemu se navedena metalna učvršćenja (205) prilagođavaju da omogućuju električni spoj između navedene primarne tekućine za grijanje i potencijala uzemljenja.
The heating system (100) according to claim 1, wherein said heat exchanger (130) is configured to provide a galvanic separation (134) of said primary heating liquid from said secondary heating liquid. 
Sustav za grijanje (100) prema tvrdnji 1, pri čemu je navedeni izmjenjivač topline (130) konfiguriran da omogući galvansko odvajanje (134) navedene primarne tekućine za grijanje iz navedene sekundarne tekućine za grijanje.
The heating system (100) according to claim 5, wherein said control unit (160) is configured to cause said electric heater (110) to apply a pulsed current with a pulse frequency to said primary heating liquid, and further to modify said pulse frequency of said pulsed current to heat said primary heating liquid on a target temperature (Temp1) and to adjust the pressure of the primary liquid to be within predetermined limits. 
Sustav za grijanje (100) prema tvrdnji 6, pri čemu je navedena kontrolna jedinica (160) konfigurirana da prouzrokuje da navedeni električni grijač (110) primijeni pulsnu struju s pulsnom frekvencijom na navedenu primarnu tekućinu za grijanje i nadalje da modificira navedenu pulsnu frekvenciju navedene pulsne struje da zagrijava navedenu primarnu tekućinu za zagrijavanje na ciljnu temperaturu (Temp1).
A pharmaceutical composition comprising S-ketamine hydrochloride and water; wherein the pharmaceutical composition does not contain an antimicrobial preservative; wherein the S-ketamine hydrochloride is present in a concentration of at least eq. 
Farmaceutski sastav koji obuhvaća S-ketamin hidroklorid i vodu; pri čemu farmaceutski sastav ne obuhvaća antimikrobni konzervans; pri čemu S-ketamin hidroklorid se nalazi u koncentraciji od najmanje ekv.
120 mg/mL, based on the total volume of the composition. 
120 mg/mL, na temelju ukupnog volumena sastava.
The pharmaceutical composition according to Claim 1, which 
Farmaceutski sastav prema zahtjevu 1, koji
additionally contains a buffer; and/or 
dodatno sadrži pufer; i/ili
The pharmaceutical composition according to Claim 1, wherein the S-ketamine hydrochloride is present in a concentration in the range of eq. 
Farmaceutski sastav prema zahtjevu 1, pri čemu S-ketamin hidroklorid se nalazi u koncentraciji u opsegu od ekv.
The pharmaceutical composition according to Claim 1, wherein the pharmaceutical composition is formulated for nasal administration. 
Farmaceutski sastav prema zahtjevu 1, pri čemu je farmaceutski sastav formuliran za nazalnu primjenu.
The pharmaceutical composition according to Claim 1, wherein the pharmaceutical composition further contains a buffer. 
Farmaceutski sastav prema zahtjevu 1, pri čemu farmaceutski sastav dalje sadrži pufer.
The pharmaceutical composition according to Claim 5, wherein the buffer is 1N NaOH. 
Farmaceutski sastav prema zahtjevu 5, pri čemu je pufer 1N NaOH.
The pharmaceutical composition according to Claim 5, wherein the buffer is present in an amount sufficient to adjust the pH of the pharmaceutical composition to a pH in the range of from pH 3.5 to pH 6.5; or wherein the buffer is present in an amount sufficient to adjust the pH of the composition to a pH in the range of from pH 4.5 to pH 5.5. 
Farmaceutski sastav prema zahtjevu 5, pri čemu se pufer nalazi u količini koja je dovoljna da se podesi pH farmaceutskog sastava do pH u opsegu od pH 3.5 do pH 6.5; ili pri čemu se pufer nalazi u količini koja je dovoljna da se podesi pH sastava do pH u opsegu od pH 4.5 do pH 5.5.
The pharmaceutical composition according to Claim 1, wherein the pharmaceutical composition exhibits a shelf-life under accelerated storage conditions of at least 3 months. 
Farmaceutski sastav prema zahtjevu 1, pri čemu farmaceutski sastav pokazuje vrijeme trajanja pod ubrzanim uvjetima skladištenja od najmanje 3 mjeseca.
The dosage form according to claim 9, which is adapted for nasal administration. 
Oblik doziranja prema zahtjevu 9, koji je prilagođen za nazalnu primjenu.
The pharmaceutical composition according to Claim 1 or the pharmaceutical dosage form according to Claim 9 for use in the treatment of depression. 
Farmaceutski sastav prema zahtjevu 1 ili farmaceutski oblik doziranja prema zahtjevu 9 za upotrebu u liječenju depresije.
The pharmaceutical composition or the pharmaceutical dosage form for use according to claim 11, wherein the depression is selected from the group consisting of major depressive disorder, unipolar depression, treatment-refractory depression, resistant depression, anxious depression and bipolar depression. 
Farmaceutski sastav ili farmaceutski oblik doziranja za upotrebu prema zahtjevu 11, pri čemu je depresija odabrana iz grupe koja obuhvaća veliki depresivni poremećaj, unipolarnu depresiju, liječenje refraktorne depresije, rezistentnu depresiju, anksioznu depresiju i bipolarnu depresiju.
The pharmaceutical composition or the pharmaceutical dosage form for use according to claim 11, wherein the depression is selected from the group consisting of resistant depression or treatment refractory depression. 
Farmaceutski sastav ili farmaceutski oblik doziranja za upotrebu prema zahtjevu 11, pri čemu je depresija odabrana iz grupe koja obuhvaća rezistentnu depresiju ili liječenje refraktorne depresije.
A pharmaceutical composition as in Claim 1, comprising S-ketamine HCl; citric acid; disodium edetate; sodium hydroxide; and water. 
Farmaceutski sastav prema zahtjevu 1, koji obuhvaća S-ketamin HCl; limunsku kiselinu; dinatrijev edetat; natrijev hidroksid; i vodu.
disodium edetate; wherein the disodium edetate is present in an amount of about 0.12 mg/ml; 
dinatrijev edetat; pri čemu se dinatrijev edetat nalazi u količini od oko 0.12 mg/ml;
sodium hydroxide; wherein the sodium hydroxide is present in an amount sufficient to adjust the pH of the pharmaceutical composition to a pH of about 4.5; and water. 
natrijev hidroksid; pri čemu se natrijev hidroksid nalazi u količini koja je dovoljna da se podesi pH farmaceutskog sastava do pH od oko 4.5; i vodu.
A nucleic acid encoding a light chain variable region and a heavy chain variable region of the antibody or antigen binding fragment thereof of any one of claims 1 to 6. 
Nukleinska kiselina, naznačena time, da ona kodira varijabilno područje lakog lanca i varijabilno područje teškog lanca od protutijela ili njegovog fragmenta koji veže antigen u skladu s bilo kojim od zahtjeva 1 do 6.
a nucleic acid encoding a light chain variable region of the humanized antibody or antigen binding fragment thereof of any one of claims 1 to 6 and a nucleic acid encoding a heavy chain variable region of the humanized antibody or antigen binding fragment thereof of any one of claims 1 to 6, wherein each nucleic acid is on a separate vector or on the same vector; or 
nukleinsku kiselinu koja kodira varijabilno područje lakog lanca humaniziranog protutijela ili njegovog fragmenta koji veže antigen u skladu s bilo kojim od zahtjeva 1 do 6 i nukleinsku kiselinu koja kodira varijabilno područje teškog lanca humaniziranog protutijela ili njegovog fragmenta koji veže antigen u skladu s bilo kojim od zahtjeva 1 do 6, pri čemu je svaka nukleinska kiselina na zasebnom vektoru ili na istom vektoru; ili
A composition or pharmaceutical composition comprising the humanized antibody or antigen binding fragment thereof of any one of claims 1 to 7, wherein said composition further comprises a carrier and wherein said pharmaceutical composition further comprises a pharmaceutically acceptable carrier. 
Pripravak ili farmaceutski pripravak, naznačen time, da sadrži humanizirano protutijelo ili njegov fragment koji veže antigen u skladu s bilo kojim od zahtjeva 1 do 7, pri čemu navedeni pripravak dodatno sadrži nosač, te time, da navedeni farmaceutski pripravak nadalje sadrži farmaceutski prihvatljiv nosač.
The humanized antibody or antigen binding fragment thereof or composition or pharmaceutical composition for the use according to claim 13, wherein the cancer is selected from the group consisting of ovarian cancer, skin cancer, renal cancer, colorectal cancer, sarcoma, leukemia, brain cancer, thyroid cancer, breast cancer, prostate cancer, oesophageal cancer, bladder cancer, lung cancer and head and neck cancer and/or wherein the cancer is metastatic. 
Humanizirano protutijelo ili njegov fragment koji veže antigen ili pripravak ili farmaceutski pripravak za uporabu prema zahtjevu 13, naznačen time, da je rak odabran iz skupine koja se sastoji od sljedećih: rak jajnika, rak kože, rak bubrega, kolorektalni rak, sarkom, leukemija, rak mozga, rak tiroidne žlijezde, rak dojke, rak prostate, rak jednjaka, rak mjehura, rak pluća i rak glave i vrata i/ili time, da je rak metastatski.
A recombinant DNA method of making the humanized antibody or antigen binding fragment thereof of any one of claims 1 to 6, comprising culturing an isolated cell as defined in part (a) of claim 10 so that the antibody or antigen binding fragment thereof is produced. 
DNK-rekombinantni postupak za pripravu humaniziranog protutijela ili njegovog fragmenta koji veže antigen prema bilo kojem od zahtjeva 1 do 6, naznačen time, da obuhvaća kultiviranje izolirane stanice kako je definirano u dijelu (a) zahtjeva 10, te se tako proizvede protutijelo ili njegov fragment koji veže antigen.
A compound according to claim 1 or 2 for use in treating a disease or disorder selected from the group consisting of pain, cancer, inflammation or an inflammatory diseases, neurodegenerative diseases, Trypanosoma cruzi infection, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis, pelvic pain syndrome, diseases related to an imbalance of the regulation of bone remodeling, and diseases resulting from Connective Tissue Growth Factor aberrant signaling. 
Spoj u skladu s patentnim zahtjevom 1 ili 2, naznačen time što je namijenjen upotrebi u liječenju bolesti ili poremećaja kojeg se bira iz skupine koju čine bol, rak, upala ili upalne bolesti, neurodegenerativne bolesti, infekcija parazitom Trypanosoma cruzi, Sjögrenov sindrom, endometrioza, dijabetična periferna neuropatija, prostatitis, sindrom zdjelične boli, bolesti povezane s neravnotežom reguliranja preoblikovanja kostiju, te bolesti koje su posljedica pogrešnog signaliziranja čimbenika rasta vezivnog tkiva.
The compound for use according to claim 6, wherein the disease or disorder treated is pain. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 6, naznačen time što je bolest ili poremećaj kojeg se liječi bol.
The compound for use according to claim 6, wherein said disease is an inflammatory disease, preferably selected from the group consisting of inflammatory lung diseases, interstitial cystitis, painful bladder syndrome, inflammatory bowel diseases, and inflammatory skin diseases. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 6, naznačen time što je navedena bolest upalna bolest, koju se po mogućnosti bira iz skupine koju čine upalne plućne bolesti, intersticijski cistitis, sindrom bolnog mokraćnog mjehura, upalne crijevne bolesti, te upalne kožne bolesti.
The compound for use according to claim 14, in combination with an effective amount of one or more additional agents selected from the group consisting of anti-TNF agents, antimetabolite and antifolate drugs, and targeted kinase inhibitors. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 14, naznačen time što je u kombinaciji s djelotvornom količinom jednog ili više dodatnih sredstava, koja se bira iz skupine koju čine sredstva protiv TNF, antimetabolitni i antifolatni lijekovi, te inhibitori ciljanih kinaza.
The compound for use according to claim 15, in combination with an effective amount of one or more additional agents selected from the group consisting of infliximab, adalimumab, certolizumab pegol, golimumab, etanercept, Methotrexate, Ruxolitinib, Tofacitinib, CYT387, Lestaurtinib, Pacritinib and TG101348. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 15, naznačen time što je u kombinaciji s djelotvornom količinom jednog ili više dodatnih sredstava, koja se bira iz skupine koju čine infliksimab, adalimumab, certolizumab pegol, golimumab, etanercept, metotreksat, ruksolitinib, tofacitinib, CYT387, lestaurtinib, pakritinib i TG101348.
The compound for use according to claim 6, wherein the disease is a disease resulting from Connective Tissue Growth Factor aberrant signaling. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 6, naznačen time što je bolest bolest koja je posljedica pogrešnog signaliziranja čimbenika rasta vezivnog tkiva.
The compound for use according to claim 17, wherein the disease is selected from the group consisting of Raynaud's Syndrome, Idiopathic pulmonary fibrosis, scarring (hypertrophic, keloid and others), cirrhosis, endomyocardial fibrosis, atrial fibrosis, myelofibrosis, progressive massive fibrosis (lung), nephrogenic systemic fibrosis, scleroderma, systemic sclerosis, arthrofibrosis, and ocular fibrosis. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 17, naznačen time što se bolest bira iz skupine koju čine Raynaudov sindrom, idiopatska plućna fibroza, stvaranje ožiljaka (hipertrofično, keloidno i drugo), ciroza, endomiokardijalna fibroza, atrijalna fibroza, mijelofibroza, progresivna masivna fibroza (pluća), nefrogena sistemna fibroza, skleroderma, sistemna skleroza, artrofibroza, te očna fibroza.
The compound for use according to claim 20, wherein the dysregulation of TrkA comprises one or more chromosome translocations or inversions resulting in TrkA gene fusions. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 20, naznačen time što disregulacija TrkA sadrži jednu ili više kromosomskih translokacija ili inverzija, čije su posljedice fuzije gena za TrkA.
A process for the preparation of a compound of claim 1 or 2, which comprises: 
Postupak priprave spoja u skladu s patentnim zahtjevom 1 ili 2, naznačen time što se sastoji u:
reacting a compound having the formula II-A with a compound having the formula IV where L1 is a leaving group, in the presence of a base; or 
reakciji spoja koji ima formulu II-A sa spojem koji ima formulu IV, gdje je L1 izlazna skupina, u prisutnosti baze; ili
reacting a compound having the formula V where L2 is a leaving group, with a compound having the formula III in the presence of a base; or 
reakciji spoja koji ima formulu V, gdje je L2 izlazna skupina, sa spojem koji ima formulu III, u prisutnosti baze; ili
reacting a compound having the formula VI with diphenylphosphoryl azide to form an intermediate, followed by reacting the intermediate with a compound having the formula III in the presence a base; or 
reakciji spoja koji ima formulu VI s difenilfosforil-azidom kako bi se dobilo međuprodukt, za čim slijedi reakcija međuprodukta sa spojem koji ima formulu III, u prisutnosti baze; ili
An antibody according to claim 1 or claim 4, which is an isolated monoclonal antibody, or an antigen-binding portion thereof, an antibody fragment, or an antibody mimetic. 
Protutijelo za uporabu sukladno zahtjevu 1 ili zahtjevu 2, koje je izolirano monoklonsko protutijelo ili njegov dio koji veže antigen, fragment protutijela.
the presence of an elevated level of antibodies capable of immunospecific binding to Lymphocyte antigen 75 or said one or more epitope-containing fragments thereof in said subject as compared with the level in a healthy subject or 
prisutnost povišene razine protutijela sposobnih imunospecifičnog vezanja na limfocitni antigen 75 ili rečeni jedan ili više fragmenata koji sadrže epitop u navedenom subjektu u usporedbi s razinom u zdravog subjekta ili
Austenitic high-manganese stainless steel according to the claim 1, 2 or 3, characterized in that the work-hardening rate based on the cold deformation for the yield strength Rp0,2 is at least 40 % with the cold deformation degree 20 %. 
Austenitičan nehrđajući čelik s visokim udjelom mangana prema zahtjevu 1, naznačen time da je brzina hladne obrade na temelju stupnja hladne deformacije od 20 % za granicu tečenja Rp0,2 barem 40 %.
Austenitic high-manganese stainless steel according to any of the preceding claims, characterized in that the austenitic stainless steel is manufactured as slabs, blooms, billets, flat products such as coils, strips, plates, sheets, long products such as bars, rods, wires, profiles and shapes, tubular products such as pipes, tubes. 
Austenitičan nehrđajući čelik s visokim udjelom mangana prema bilo kojem od prethodnih zahtjeva, naznačen time da je austenitičan nehrđajući čelik proizveden u obliku greda, blokova, poluga, ravnih proizvoda poput zavojnica, traka, ploča, limova, dugih proizvoda poput štapova, šipki, žica, profila i oblika, cijevnih proizvoda poput cijevi, tuba.